11 Dec 2024 11:44 CET

Issuer

EXACT Therapeutics AS

Reference is made to the stock exchange announcements published on 3 December
2024 by EXACT Therapeutics AS' ("EXACT-Tx" or the "Company") regarding the
successful placement of 31,182,795 new shares, of which 9,624,150 shares shall
be issued in tranche 1 (the "Tranche 1 Offer Shares").

The issuance of the Tranche 1 Offer Shares has now been registered with the
Norwegian Register of Business Enterprises (Nw: Foretaksregisteret). Following
registration of the share capital increase, the Company’s share capital is NOK
166,818.808 divided into 41,704,702 shares, each with a par value of NOK 0.004.

This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.

For more information, please contact:

Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of
ultrasound and microbubbles to enable targeted drug delivery in oncology.
Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to
a wide range of therapeutic agents within oncology and across a multitude of
other indications including brain diseases. www.exact-tx.com


Source

EXACT Therapeutics AS

Provider

Oslo Børs Newspoint

Company Name

EXACT THERAPEUTICS

ISIN

NO0010852213

Symbol

EXTX

Market

Euronext Growth